Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
A patient took two doses of Vivotif, two days in a row instead of alternated days.; Case reference number US-BN-2024-002104 is a spontaneous case initially received from a nurse via agency (reference number: USBAV24-1494) on 26-Jun-2024 and concerns a patient of unknown demographics. The patient's medical history and concomitant medication details were not provided. On unspecified dates, reported as two days in a row instead of alternated days, the patient took the first and the second dose of Vivotif (batch number: unknown), at an unknown dose, orally, for an unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccination. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240626-c8986f to US-BAVARIAN NORDIC A/S-US-BN-2024-002104, in accordance with guidance on WWID formatting.; Reporter's Comments: A patient of unknown demographics took the first and the second dose of Vivotif, at an unknown dose, orally, for an unknown indication which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif vaccination. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unknown demographics took the first and the second dose of Vivotif, at an unknown dose, orally, for an unknown indication which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif vaccination. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.